Thoughts on Today's Press Release
1. The shelf offering will give SNTA a stronger bargaining position with partnership discussions. Hopefully it won't have to be used.
2. The elesclomol news was encouraging.
3. Even more investigator-sponsored trials are in the works. Can't hurt,
It seems like Mr. Market is overreacting.